Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.

This study found that selective androgen receptor modulators (SARMs) significantly inhibited tumor growth and metastasis-promoting factors in AR-positive triple-negative breast cancer models.

This review discusses androgen receptor targeting as a potential treatment strategy for triple-negative breast cancer and reports no new experimental outcomes.

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

This study observed that putrescine and HR form a negative feedback mechanism affecting hair cycling, indicating a significant connection between HR, polyamines, and hair growth regulation.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This case report highlights the challenge of diagnosing systemic lupus erythematosus in males and antinuclear antibody-negative patients, emphasizing the need for primary care doctors to maintain a high suspicion of the condition.

This study suggests that hair loss disorders like Marie Unna hereditary hypotrichosis may result from mutations that disrupt post-transcriptional regulation of HR protein expression by PCPB2 interacting with Hr mRNA.

In this study, anal beta-papillomavirus infection was found to be highly prevalent among Slovenian MSM, with higher rates observed in HIV-1 positive individuals and those using alkyl nitrates.

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.

This study found that a homeopathic product reduced skin lesions and oxidative stress related to atopic dermatitis in dogs.

This case report highlights the first known instance of ANA-negative systemic lupus erythematosus presenting as spontaneous coronary artery dissection, emphasizing a need for rheumatological evaluation in such patients.

This case report illustrates that Leydig cell tumors, despite causing significantly elevated androgen levels, can be difficult to localize due to their small size, as demonstrated in a 42-year-old woman whose tumor was only identified after oophorectomy.

This study found that both Glycyrrhiza glabra and Emblica officinalis extracts demonstrated significant antibacterial activity against Escherichia coli, with the highest effect seen in 100% crude extracts.

This study reported that 100% crude extracts of Glycyrrhiza glabra and Emblica officinalis demonstrated strong antibacterial effects against Escherichia coli.

This study found that compounds isolated from the Etlingera alba rhizome exhibited cytotoxic and anti-metastatic activity, with potential for development against Triple-Negative Breast Cancer.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

In this study, among Indian patients with triple-negative breast cancer, Ki-67 expression levels were high but not significantly associated with treatment response to a neoadjuvant docetaxel-carboplatin regimen, which showed complete clinical, imaging, and pathological response rates of 39.13%, 34.78%, and 47.61%, respectively.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This study identified the safest groups of shampoos based on their harmful components, price, and consumer assessments, recommending specific options for health-conscious consumers.

This study found that women recovering from cancer developed a positive body image by focusing on acceptance and newfound trust in their bodies, despite the trauma of illness.

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

In this study, a 37-year-old female with resistant hypertension and signs of Cushing's syndrome and primary aldosteronism was found to have normal cortisol levels but high levels of cortisol and aldosterone via adrenal venous sampling, leading to a diagnosis confirmed by right adrenalectomy.

This study found that B cells have dual roles in tumor immunity, with regulatory B cells potentially hindering immune responses against tumors in the melanoma mouse model.

This study found that the receptor kinase RHS10 negatively regulates root hair growth in Arabidopsis thaliana by modulating growth duration and is associated with cell wall signal mediation, involving RNA catabolism and ROS accumulation.

These plant extracts can kill some bacteria.

Vitamin D receptor mutations can cause alopecia by affecting hair growth genes.

This article reviews the care of transgender patients, encompassing diagnosis, treatment options, and challenges in health care access, but does not present new research findings; the authors emphasize the critical role of providers in addressing transgender health needs.